Press Releases

WATERTOWN, MASS .--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced it has been issued US patent No. 8,192,408 titled "Ocular Trocar Assembly" for a new inserter

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the National Authority of Medicines and Health Products (Autoridade Nacional do Medicamento e

pSivida Corp. Announces Expiration of 2.7 Million Warrants WATERTOWN, Mass. --(BUSINESS WIRE)--May. 17, 2012-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the expiration on May

pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2012 WATERTOWN, Mass. --(BUSINESS WIRE)--May. 9, 2012-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial

pSivida Corp. Announces United Kingdom Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema WATERTOWN, Mass.--(BUSINESS WIRE)--May. 7, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment

pSivida Corp Announces Third Quarter 2012 Financial Results Release Date and Conference Call Information WATERTOWN, Mass.--(BUSINESS WIRE)--May. 3, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

pSivida Corp. Announces ILUVIEN(R) Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema WATERTOWN, Mass., Apr 24, 2012 (BUSINESS WIRE) --pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment

pSivida Announces Second Tech Evaluation Agreement with its BioErodible Durasert Technology WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 13, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today

pSivida Corp. Names Douglas Godshall to Board of Directors WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 6, 2012-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected

• ILUVIEN® expected to be the first sustained release pharmaceutical in the European Union (EU) to treat diabetic macular edema (DME)
• ILUVIEN expected to be indicated for chronic DME considered insufficiently responsive to available therapies

pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2011 WATERTOWN, Mass. --(BUSINESS WIRE)--Feb. 8, 2012-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced

pSivida CEO to Present at 14th Annual BioCEO & Investor Conference February 14 WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 6, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that

pSivida CEO to Participate in Panel at Glaucoma 360 Conference February 3 WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 2, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its

pSivida Corp Announces Second Quarter 2012 Financial Results Release Date and Conference Call Information WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 1, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

pSivida Announces Tech Evaluation Agreement with Leading Pharmaceutical Company WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 22, 2011-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that

pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN(R) for DME WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 11, 2011-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN(R) for DME and pSivida's Product Pipeline WATERTOWN, Mass., Nov 11, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in developing sustained release, drug delivery products

pSivida Corp. Reports Results for the First Quarter Ended September 30, 2011 WATERTOWN, Mass., Nov 07, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced

pSivida Corp. Announces First Quarter 2012 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., Oct 31, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

Second Consecutive Year Company Achieves Ranking